IRRA Fair Value & Analysis

Healthcare · ID · Market cap 561B IDR

Below-average quality, screening 100% undervalued on our models.

What matters now

• The large discount to fair value meets weak quality (35/100). That raises the risk this is a value trap rather than a bargain.
• The price is below even our cautious bear case (554.11 IDR). The market is more pessimistic than our downside scenario.
• A fairly wide model range (554.11 IDR to 1,237 IDR) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.

How to read this chart

60‑month range 330.00 IDR – 2,436 IDR · fair‑value band 554.11 IDR – 1,237 IDR · the 370.00 IDR price screens below the 738.81 IDR fair value. Dashed = 300-day average. As of Jul 16, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

IRRA (IRRA) currently trades at 370.00 IDR, while our model-based Fair Value estimate is 738.81 IDR, implying the stock looks roughly 99.7% undervalued today. The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, IRRA generated revenue of 1.1T IDR at a net margin of 6.0%. Revenue grew 1.2% year over year. It earns a return on equity of 11.9%. Net debt stands at 756B IDR. Fundamentals as of Jul 16, 2026

Our scenario range runs from 554.11 IDR (bear case) to 1,237 IDR (bull case); at 370.00 IDR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 40% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at 100%, IRRA screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (1,976 IDR) versus Asset-Based (256.76 IDR). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

PT Itama Ranoraya Tbk wholesale trades in laboratory and pharmaceutical equipment, and medical devices for humans in Indonesia.

Full company description

PT Itama Ranoraya Tbk wholesale trades in laboratory and pharmaceutical equipment, and medical devices for humans in Indonesia. It offers in vitro diagnostics products comprising rapid test, serology, glucose diagnostic, NAPZA test, and clinical laboratory; medical imaging products, including bone densitometer, C-arm, flat panel digital detector, mobile and stationary x-ray, and mammography; nefrology, blood and transfusion, orthopedic, radiotherapy, and surgical products; and hospital supplies and hospital kitchen equipment. The company also provides cold chain management, such as cold room, bloodbank, and pharmaceutical refrigerator; critical care; and pharmaceutical supplements, as well as maternal and neonatal care products. In addition, it leases office space. It sells its products under the oneject, Abbott, Terumo, DIRUI, Medtronic, mindray, ZOLL, Sansin, Vestfrost, ASCENSIA, Hemocue, CUREXO, SATInc., PT. MEGA, Planmed, Sinmed, Balmed, KSM CARE, Trisan Care, Shamrock, OTORO, GEA, Hologic, IS, Avimac, RadmediX, and SMAM brand names. The company was founded in 1988 and is based in Jakarta Timur, Indonesia. PT Itama Ranoraya Tbk operates as a subsidiary of PT Global Dinamika Kencana.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

IRRA reported revenue of 1.1T IDR in FY2025 versus 1.3T IDR in FY2021, a compound −4.4%/yr. Reported net income was 65.5B IDR in FY2025, compounding −12.6%/yr from FY2021.

Watch IRRA: get an alert when its fair value changes →

Peer Group

Medical Distribution · 81 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Distribution median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.